Stefano Gullà

Stefano Gullà has a long and distinguished career in the biotech and pharmaceutical industry. Stefano began their career in 2001 as an Associate Scientist at SBH Science. From 2003 to 2009, they were a Graduate Student and Advisor at Northeastern University. From 2009 to 2010, they were a Postdoctoral Associate and Fellow at MIT. From 2010 to 2015, they were a Project Leader, Principal Scientist, and Senior Scientist at Pfizer. From 2015 to 2016, they were a Program Manager and Portfolio Manager at Agenus. From 2016 to 2021, they were the CEO, CSO, and Founder of Abcuro, Inc., where they leveraged their extensive biotech and pharma industry knowledge to develop a new class of immune modulatory biotherapeutics for treating autoimmunity and cancer. From 2021 to 2022, they were the Senior Director of Pharmacology and Preclinical Development at Repertoire Immune Medicines. Stefano is currently the VP of Biology Head and Protein Therapeutics at RVAC Medicines.

Stefano Gullà's education history is as follows: Stefano earned their Diploma from Liceo Scientifico in 2007. From 1998 to 2001, they obtained their Ph.D in Biophysical Chemistry from Northeastern University. Stefano then obtained their B.S in Biochemistry from Northeastern University. From 2004 to 2008, they obtained their Doctor of Philosophy (Ph.D.) in Biophysics from Northeastern University. Lastly, they completed a Postdoc in Protein-protein interaction at the Massachusetts Institute of Technology from 2008 to 2010.